DR. ILSEUNG CHO, M.D.
Osteopathic Medicine in New York, NY
License number
New York 235636
Category
Osteopathic Medicine
Type
Gastroenterology
Address
Address
423 St 11 NORTH UNIT GI, New York, NY 10010
Phone
(212) 686-7500
Personal information
See more information about ILSEUNG CHO at radaris.comName
Address
Phone
215 E 95Th St APT 14F, New York, NY 10128
435 E 30Th St #1224, New York, NY 10016
435 30Th St, New York, NY 10016
545 1St Ave, New York, NY 10016
Organization information
See more information about ILSEUNG CHO at bizstanding.comIlseung Cho MD
423 E 23 St, New York, NY 10010
Industry:
Internist
Phone:
(212) 686-7500 (Phone)
Ilseung Cho
Bellevue Hospital - Ilseung Cho MD
462 1 Ave, Frnt, New York, NY 10016
Categories:
Gastroenterology Physicians & Surgeons
Phone:
(212) 263-7300 (Phone)
Professional information
See more information about ILSEUNG CHO at trustoria.com
Ilseung Cho, New York NY
Ilseung Cho, New York NY
Specialties:
Gastroenterologist
Address:
423 E 23Rd St, New York, NY 10010
Education:
Doctor of Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine, American Board of Internal Medicine Sub-certificate in Gastroenterology (Internal Medicine)
Dr. Ilseung Cho, New York NY - MD (Doctor of Medicine)
Dr. Ilseung Cho, New York NY - MD (Doctor of Medicine)
Specialties:
Gastroenterology
Address:
423 E 23Rd St, New York 10010
(212) 686-7500 (Phone)
(212) 686-7500 (Phone)
Certifications:
Gastroenterology, 2008, Internal Medicine, 2005
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 2002
New York University
Graduated: 2002
Ilseung Cho, New York NY
Ilseung Cho, New York NY
Work:
Manhattan Campus of the VA NY Harbor Healthcare System
423 E 23Rd St, New York, NY 10010
423 E 23Rd St, New York, NY 10010
Compositions And Methods For Treating Obesity And Related Disorders By Characterizing And Restoring Mammalian Bacterial Microbiota
Compositions And Methods For Treating Obesity And Related Disorders By Characterizing And Restoring Mammalian Bacterial Microbiota
US Patent:
2012005, Mar 8, 2012
Filed:
Aug 19, 2011
Appl. No.:
13/214034
Inventors:
Martin J. Blaser - New York NY, US
Laura Nondorf - Brooklyn NY, US
Ilseung Cho - New York NY, US
Bart Waters - Midland MI, US
Laura Nondorf - Brooklyn NY, US
Ilseung Cho - New York NY, US
Bart Waters - Midland MI, US
Assignee:
DOW GLOBAL TECHNOLOGIES LLC - Midland MI
NEW YORK UNIVERSITY - New York NY
NEW YORK UNIVERSITY - New York NY
International Classification:
A61K 35/74, A61P 3/04, A61P 9/10, A61P 3/06, A61P 3/00, C12Q 1/68, A61P 3/08
US Classification:
424 9341, 435 612, 424 934, 424 9345
Abstract:
The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.
Compositions And Methods For Characterizing And Restoring Gastrointestinal, Skin, And Nasal Microbiota
Compositions And Methods For Characterizing And Restoring Gastrointestinal, Skin, And Nasal Microbiota
US Patent:
2010007, Mar 25, 2010
Filed:
Sep 25, 2009
Appl. No.:
12/566965
Inventors:
Martin J. Blaser - New York NY, US
Ilseung Cho - New York NY, US
Ilseung Cho - New York NY, US
Assignee:
NEW YORK UNIVERSITY - New York NY
International Classification:
A61K 35/74, A61P 31/00, A61P 11/06, A61P 7/12, A61P 3/00
US Classification:
424 934
Abstract:
The present invention relates to characterizing changes in mammalian bacterial gastrointestinal, cutaneous and nasal microbiota associated with antibiotic treatment and various disease conditions (such as asthma, allergy, obesity, metabolic syndrome, gastrointestinal reflux disease (GERD), eosinophilic esophagitis, gastro-esophageal junction adenocarcinomas (GEJAC), infections due to bacteria that are resistant to antibiotics, including Methicillin-resistant (MRSA), , vancomycin-resistant enterococci, etc.) and related diagnostic and therapeutic methods. Therapeutic methods of the invention involve the use of live bacterial inoculants that are capable of restoring healthy mammalian bacterial gastrointestinal, skin, and nasal microbiota.